primary Reason 4 O O
objectives Reason 4 O O
and Reason 4 O O
early Reason 4 O O
data Reason 4 O O
from Reason 4 O O
a Reason 4 O O
phase Reason 4 O O
1 Reason 4 O O
trial Reason 4 O O
presented Reason 4 O O
at Reason 4 O O
the Reason 4 O O
virtual Reason 4 O O
AACR Reason 4 O O
Annual Reason 4 O O
Meeting Reason 4 O O
regarding Reason 4 O O
the Reason 4 O O
neoantigen Reason 4 O O
peptide Reason 4 O O
vaccine, Reason 4 O O
PGV-001. Reason 4 O O
Thomas Reason 4 O O
Marron, Reason 4 O O
MD, Reason 4 O O
PhD, Reason 4 O O
of Reason 4 O O
the Reason 4 O O
Icahn Reason 4 O O
School Reason 4 O O
of Reason 4 O O
Medicine Reason 4 O O
at Reason 4 O O
Mount Reason 4 O O
Sinai, Reason 4 O O
spoke Reason 4 O O
with Reason 4 O O
CancerNetwork Reason 4 O O
about Reason 4 O O
the Reason 4 O O
data Reason 4 O O
and Reason 4 O O
primary Reason 4 O O
objectives Reason 4 O O
of Reason 4 O O
the Reason 4 O O
phase Reason 4 O O
1 Reason 4 O O
trial Reason 4 O O
presented Reason 4 O O
at Reason 4 O O
the Reason 4 O O
virtual Reason 4 O O
AACR Reason 4 O O
Annual Reason 4 O O
Meeting Reason 4 O O
investigating Reason 4 O O
PGV-001, Reason 4 O O
a Reason 4 O O
neoantigen Reason 4 O O
peptide Reason 4 O O
vaccine, Reason 4 O O
in Reason 4 O O
a Reason 4 O O
cohort Reason 4 O O
of Reason 4 O O
15 Reason 4 O O
patients. Reason 4 O O
Transcription:This O O O O
was O O O O
a O O O O
phase O O O O
1 O O O O
trial O O O O
and O O O O
so O O O O
the O O O O
primary O O O O
objectives O O O O
were O O O O
really O O O O
threefold. O O O O
First, Reason 5 O O
we Reason 5 O O
wanted Reason 5 O O
to Reason 5 O O
determine Reason 5 O O
the Reason 5 O O
safety Reason 5 O O
and Reason 5 O O
tolerability Reason 5 O O
of Reason 5 O O
the Reason 5 O O
vaccine. Reason 5 O O
We Reason 5 O O
wanted Reason 5 O O
to Reason 5 O O
determine Reason 5 O O
the Reason 5 O O
feasibility Reason 5 O O
of Reason 5 O O
creating Reason 5 O O
the Reason 5 O O
vaccine Reason 5 O O
both Reason 5 O O
using Reason 5 O O
our Reason 5 O O
pipeline Reason 5 O O
to Reason 5 O O
identify Reason 5 O O
neoantigens Reason 5 O O
and Reason 5 O O
then Reason 5 O O
actually Reason 5 O O
successfully Reason 5 O O
synthesizing Reason 5 O O
those Reason 5 O O
peptides. Reason 5 O O
And Reason 5 O O
then Reason 5 O O
finally, Reason 5 O O
to Reason 5 O O
find Reason 5 O O
the Reason 5 O O
immunogenicity Reason 5 O O
of Reason 5 O O
the Reason 5 O O
vaccine. Reason 5 O O
The O O O O
adjuvant O O O O
space O O O O
is O O O O
a O O O O
very O O O O
tough O O O O
space O O O O
to O O O O
look O O O O
for O O O O
actual O O O O
clinical O O O O
efficacy O O O O
and O O O O
so O O O O
only O O O O
with O O O O
longer O O O O
term O O O O
follow O O O O
up O O O O
are O O O O
we O O O O
really O O O O
going O O O O
to O O O O
be O O O O
able O O O O
to O O O O
say O O O O
anything O O O O
about O O O O
that, O O O O
and O O O O
we O O O O
really O O O O
would O O O O
need O O O O
larger O O O O
trials O O O O
to O O O O
look O O O O
at O O O O
clinical O O O O
efficacy, O O O O
but O O O O
that O O O O
is O O O O
obviously O O O O
one O O O O
of O O O O
the O O O O
secondary O O O O
objectives. O O O O
But Reason 5 O O
our Reason 5 O O
primary Reason 5 O O
objective, Reason 5 O O
as Reason 5 O O
far Reason 5 O O
as Reason 5 O O
determining Reason 5 O O
the Reason 5 O O
safety Reason 5 O O
and Reason 5 O O
tolerability, Reason 5 O O
this Reason 5 O O
was Reason 5 O O
a Reason 5 O O
very Reason 5 O O
safe, Reason 5 O O
well Reason 5 O O
tolerated Reason 5 O O
therapy. Reason 5 O O
It O O O O
does O O O O
require O O O O
a O O O O
lot O O O O
of O O O O
visits, O O O O
that O O O O
was O O O O
probably O O O O
the O O O O
most O O O O
pressing O O O O
adverse O O O O
event, O O O O
although O O O O
I O O O O
don't O O O O
think O O O O
that O O O O
we O O O O
grade O O O O
number O O O O
of O O O O
visits O O O O
as O O O O
an O O O O
adverse O O O O
event. O O O O
But O O O O
really, O O O O
patients O O O O
with O O O O
only O O O O
a O O O O
few O O O O
instances O O O O
of O O O O
injection O O O O
site O O O O
reactions O O O O
and O O O O
1 O O O O
patient O O O O
had O O O O
a O O O O
low-grade O O O O
fever, O O O O
we O O O O
really O O O O
didn't O O O O
have O O O O
any O O O O
other O O O O
toxicity O O O O
concern. O O O O
The O O O O
vaccine O O O O
was O O O O
successfully O O O O
synthesized O O O O
for O O O O
13 O O O O
patients O O O O
and O O O O
it O O O O
was O O O O
administered O O O O
to O O O O
13 O O O O
patients. O O O O
All O O O O
but O O O O
2 O O O O
patients O O O O
received O O O O
all O O O O
10 O O O O
vaccines O O O O
really O O O O
over O O O O
the O O O O
course O O O O
of O O O O
6 O O O O
months. O O O O
There O O O O
was O O O O
1 O O O O
patient O O O O
who O O O O
only O O O O
received O O O O
9 O O O O
vaccines O O O O
and O O O O
another O O O O
that O O O O
received O O O O
7 O O O O
vaccines. O O O O
That O O O O
patient O O O O
actually, O O O O
unfortunately O O O O
at O O O O
that O O O O
point, O O O O
had O O O O
recurrent O O O O
disease O O O O
also O O O O
with O O O O
pretty O O O O
aggressive O O O O
biology O O O O
